Patients remain at the center of everything we do at GlycoMimetics. Through collaboration with our investigative partners, we are conducting clinical studies that explore the use of product candidates developed by our scientists in different hematological and oncologic settings. Our central goal is to obtain the data required for review and approval by regulatory authorities, such as the U.S. Food and Drug Administration.
- Rivipansel: The Phase 3 RESET trial (NCT02187003) plans to enroll approximately 350 patients ages six and older with
sickle cell disease (SCD) and a diagnosis of vaso-occlusive crisis (VOC) requiring hospital admission to receive opioid
treatment for pain management.
Learn more about the RESET study at resetsicklecell.com.
- Uproleselan (GMI-1271): This pivotal Phase 3 trial (NCT03616470) plans to enroll 380 patients ages 18 to 75 with
relapsed/refractory acute myeloid leukemia who are considered to be medically eligible to receive intensive
To learn more about other clinical trials involving our product candidates, please visit ClinicalTrials.gov. ClinicalTrials.gov is a registry of publicly and privately supported clinical studies involving human participants conducted around the world. To find information on trials run by GlycoMimetics, our development partners, or by independent investigators, use the “Search for Studies” function and enter the product candidates name (e.g., uproleselan).